Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,578.00 +0.43%
EUR-USD 1.2577 0.1759%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 91.24 +0.42%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: -
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

Cygene Laboratories Inc

CYGE:US

Ticker Delisted

Snapshot for Cygene Laboratories Inc (CYGE)

Open: - Day's Range: - Volume: 0 Bid: -
Previous Close: - 52wk Range: - 1-Yr Rtn: - Ask: -

Stock Chart for CYGE

No chart data available.
  • CYGE:US 0.0000
  • 1M
  • 1Y
0.0000
Interactive CYGE Chart

Previous Close

Key Statistics for CYGE

Current P/E Ratio (ttm) -
Estimated P/E (-) -
Earnings Per Share () (ttm) -0.0930
Est. EPS -
Est. PEG Ratio -
Market Cap (M USD) 0.00
Shares Outstanding (M) 58.02
Enterprise Value (M USD) (ttm) -
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement -
More CYGE Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for CYGE

No data available.

Company Profile & Key Executives for CYGE

CyGene Laboratories Inc. is seeking to market commercialized genetic testing to the public. The Company develops proprietary and automated DNA and RNA testing systems for the screening, monitoring, and diagnosis of human, veterinary, and plant diseases. CyGene's primary development focus is blood screening tests for the West Nile Virus and the detection of biological warfare agents.

Martin MunzerPresident/CEOBarry H DvorchikVP:Drug Development
Peter J LaurenceVP:Business DevelopmentJeffrey PincoDirector:Laboratory
More Company Profile & Key Executives for CYGE

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements